Ionis Pharmaceuticals (IONS) Q1 2026 Earnings
How Did IONS Stock React to Q1 2026 Earnings?
S&P 500 over the same 30 days: +6.60%.
Did IONS Beat Earnings? Q1 2026 Results
Yes. Ionis Pharmaceuticals reported Q1 2026 earnings of $-0.56 a share on Apr 29, 2026, beating the $-0.78 consensus estimate by 27.7%. Revenue was $246.0M against a $196.0M estimate.
Ionis Pharmaceuticals delivered a strong first-quarter 2026 beat on both the top and bottom lines, with revenue of $246.00 million coming in 25.50% ahead of the $196.01 million consensus and rising 86.9% from the year-ago period, while a GAAP loss of $0.56 per share beat the $0.78 consensus estimate by 27.74%. The primary engine behind the outperformance was an surge in R&D revenue to $138.00 million, fueled by roughly $95.00 million in clinical and regulatory milestone payments from partner agreements, complemented by 42% growth in commercial revenue to $108.00 million as newer products TRYNGOLZA and DAWNZERA gained traction. Management responded to the momentum by raising full-year 2026 total revenue guidance to $875.00 million to $900.00 million and boosting peak net sales expectations for olezarsen in severe hypertriglyceridemia to more than $3.00 billion, while the company keeps its sights on cash-flow breakeven by 2028 amid a busy regulatory calendar that includes three PDUFA dates and major cardiovascular outcomes trial readouts later this year.
- 87% year-over-year revenue growth driven by commercial success and substantial R&D milestone payments
- TRYNGOLZA showing increasing demand in FCS driven by strong launch execution
- DAWNZERA sales increased 125% sequentially versus Q4 2025
- Approximately $95 million in clinical and regulatory milestone payments from multiple partnerships
- Commercial revenue increased 42% year-over-year to $108 million
“Ionis' strong performance in the first quarter of 2026 underscores the strength of our commercial and R&D engines. Our independent launches are increasingly contributing to revenue, driven by strong commercial execution, and we are on track for two additional groundbreaking independent launches in 2026 — olezarsen for severe hypertriglyceridemia, our first medicine for a broad patient population, and zilganersen for Alexander disease, the first launch from our leading neurology pipeline.”
Ionis Pharmaceuticals CEO, on the earnings call
What Was Ionis Pharmaceuticals's Outlook in Q1 2026?
Ionis raised its full-year 2026 financial guidance: total revenue now expected at $875–$900 million (up from $800–$825 million), non-GAAP operating loss narrowed to $425–$475 million (from $500–$550 million), TRYNGOLZA full-year product sales guided at $100–$110 million, DAWNZERA full-year product sales guided at $110–$120 million, and cash/short-term investments expected to remain above $1.6 billion. The company increased peak net sales guidance for olezarsen in sHTG to >$3 billion from >$2 billion. Ionis reiterated its goal of reaching cash-flow breakeven in 2028. Key upcoming catalysts include PDUFA dates for olezarsen in sHTG (June 30, 2026), zilganersen for Alexander disease (September 22, 2026), and bepirovirsen for chronic hepatitis B (October 26, 2026), as well as Phase 3 outcomes data for pelacarsen (Lp(a) HORIZON) and eplontersen (CARDIO-TTRansform) cardiovascular outcomes trials later in 2026.
IONS YoY Financials
| Metric | Q1 2026 | Q1 2025 | Year over year |
|---|---|---|---|
| Revenue | $246.0M | $131.6M | +86.9% |
| Gross Profit | $243.0M | $130.1M | +86.8% |
| Operating Income | −$118.0M | −$98.6M | +19.7% |
| Net Income | −$93.0M | −$68.0M | +36.7% |
IONS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.